ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen

by · The Cerbat Gem

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts also recently weighed in on PRQR. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.80.

Check Out Our Latest Research Report on ProQR Therapeutics

ProQR Therapeutics Trading Up 5.8%

Shares of PRQR opened at $1.82 on Friday. The firm has a market cap of $191.76 million, a PE ratio of -3.96 and a beta of 0.21. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The stock has a fifty day moving average price of $1.64 and a 200-day moving average price of $2.06.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The business had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $6.12 million. As a group, research analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in shares of ProQR Therapeutics by 699.3% in the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the period. Sio Capital Management LLC boosted its position in ProQR Therapeutics by 1.0% in the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 20,546 shares during the last quarter. Walleye Capital LLC boosted its position in ProQR Therapeutics by 5.6% in the second quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 28,413 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in ProQR Therapeutics by 6.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after buying an additional 215,000 shares during the period. Finally, Bank of America Corp DE raised its position in ProQR Therapeutics by 25.7% during the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 24,347 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

Read More